Han Jiongping, Li Dan, Luo Hongqiang, Chen Zhe, Feng Yi, Liu Fang, Wang Liping, Huang Xin, Feng Weiying
Department of Hematology, Shaoxing People's Hospital, Shaoxing, People's Republic of China.
Department of Laboratory Medicine, Shaoxing People's Hospital, Shaoxing, People's Republic of China.
Hematology. 2025 Dec;30(1):2525012. doi: 10.1080/16078454.2025.2525012. Epub 2025 Jul 1.
Near early T-cell precursor acute lymphoblastic leukemia represents a distinct subtype of T-cell acute lymphoblastic leukemia characterized by specific immunophenotypic and molecular biological characteristics. Currently, no standardized treatment protocol exists.
This study presents a case of near early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) characterized by plasmacytoid dendritic cell proliferation, which manifested clinically through pancytopenia and generalized multiple rashes.
The patient underwent successful treatment with chemotherapy consisting of Venetoclax combined with HAG regimen administered for one cycle.
This case report provides preliminary evidence suggesting that the combination of Venetoclax with HAG (homoharringtonine, cytarabine, and granulocyte colony-stimulating factor) regimen may constitute an effective and tolerable therapeutic approach for patients with near ETP-ALL. However, these initial observations necessitate further validation through comprehensive clinical studies with larger sample sizes to definitively establish the treatment's efficacy and safety profile.
近早期T细胞前体急性淋巴细胞白血病是T细胞急性淋巴细胞白血病的一种独特亚型，具有特定的免疫表型和分子生物学特征。目前，尚无标准化的治疗方案。
本研究报告了一例以浆细胞样树突状细胞增殖为特征的近早期T细胞前体急性淋巴细胞白血病（ETP-ALL）病例，临床表现为全血细胞减少和全身性多发皮疹。
患者接受了由维奈克拉联合HAG方案组成的化疗，为期一个周期，治疗成功。
本病例报告提供了初步证据，表明维奈克拉与HAG（高三尖杉酯碱、阿糖胞苷和粒细胞集落刺激因子）方案联合使用可能是近ETP-ALL患者有效且可耐受的治疗方法。然而，这些初步观察结果需要通过更大样本量的综合临床研究进一步验证，以明确确定该治疗方法的疗效和安全性。
